|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Intermountain Health Care, Inc. Deseret Foundation |
| Information provided by: | Intermountain Health Care, Inc. |
| ClinicalTrials.gov Identifier: | NCT00465855 |
Purpose
This randomized trial will investigate important clinical outcomes of patients with acute carbon monoxide poisoning randomized to receive either one or three hyperbaric oxygen treatments.
| Condition | Intervention | Phase |
|
Carbon Monoxide Poisoning |
Procedure: Hyperbaric oxygen therapy (HBO2) |
Phase IV |
| MedlinePlus related topics: | Carbon Monoxide Poisoning Poisoning |
| ChemIDplus related topics: | Carbon monoxide |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Randomized Trial of One Versus Three Hyperbaric Oxygen Treatments for Acute CO Poisoning |
| Estimated Enrollment: | 200 |
| Study Start Date: | April 2007 |
| Estimated Study Completion Date: | May 2009 |
All patients presenting with acute carbon monoxide poisoning will receive one hyperbaric oxygen treatment (barring contraindications for hyperbaric oxygen therapy). After this treatment, eligible patients who provide consent will be randomly allocated to receive two sham sessions, or two additional hyperbaric oxygen sessions administered in a double-blind fashion.
Outcome measures will be administered at 6 weeks and 6 months.
Eligibility
| Ages Eligible for Study: | 18 Years to 79 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Lindell K. Weaver, MD | 801-408-3623 | lindell.weaver@intermountainmail.org |
| Contact: Susan K. Churchill, APRN-NP | 801-408-3623 | susan.churchill@intermountainmail.org |
| United States, Utah | |||||
| Intermountain LDS Hospital | Recruiting | ||||
| Salt Lake City, Utah, United States, 84143 | |||||
| Intermountain Medical Center | Not yet recruiting | ||||
| Salt Lake City, Utah, United States, 84157-7000 | |||||
| Intermountain Health Care, Inc. |
| Deseret Foundation |
| Principal Investigator: | Lindell K Weaver, MD | Intermountain Health Care, Inc. |
More Information
| Study ID Numbers: | 1002700 |
| First Received: | April 23, 2007 |
| Last Updated: | April 23, 2007 |
| ClinicalTrials.gov Identifier: | NCT00465855 |
| Health Authority: | United States: Institutional Review Board |
|
|
|